Poolbeg Pharma plc (LON:POLB), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has appointed Singer Capital Markets as Joint Broker with immediate effect. finnCap Ltd will continue to act as Nominated Adviser and Joint Broker alongside J&E Davy as additional Joint Broker.
AI-discovered drugs achieve Superior Success Rates in clinical trials
New research published in the journal Drug Discovery Today reveals that drugs discovered through artificial intelligence (AI) have a significantly higher success rate in Phase I clinical trials (80-90%) compared to those discovered by humans (40-65%).